Cardiovascular Systems losses narrow in 2010 Q1, due to increased sales
Cardiovascular (CV) Systems, a developer of interventional treatment systems for vascular disease, has reported financial results for its fiscal first quarter of 2010, which ended Sept. 30.

St. Paul, Minn.-based CV Systems said its revenues in the first quarter of fiscal 2010 rose to $15.2 million, a 30 percent increase over revenue of $11.6 million in the 2009 first quarter fiscal year. As a result, the company's net loss improved 55 percent to $6.2 million in the first quarter of fiscal 2010, from $13.7 million in the year-ago period.

Also, the company managed to decrease operating expenses by 18 percent, due to “effective expense management, the year-earlier write-off of $1.7 million in IPO costs and completion and timing of development projects and clinical studies.”

“Balancing revenue growth with effective expense management helped drive a substantial reduction in our loss from the fiscal 2009 first quarter, moving [CV Systems] toward our goal of profitability,” said David L. Martin, the company’s president and CEO. “During the quarter, we focused on driving adoption in existing accounts, including re-educating physicians on proper clinical protocols for using the Diamondback 360° to change lesion compliance in vessels above the knee. As a result, we are seeing greater product usage in many accounts. These improvements were offset by seasonal weakness in endovascular procedures, resulting in revenue slightly below our expected range.”